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cohort 4 (last cohort) is being treated. Median age was 54
(range 45-68). Median number of prior lines of therapy was 3
(range 2-6) and 7 subjects had previously received AHSCT.
Median CD34+ dose was 4.6 x 106/kg (range 2.21-9.34).
Median time for neutrophil engraftment was 11 days (range
8-15) and for platelet engraftment 18 days (range 11-24).
There were no non-hematologic grade 4 toxicities. The most
frequent grade 3 toxicity was infection in 8/14 subjects
consisting of 1 episode of pneumonia, 1 episode of bacter-
emia, 1 episode of urinary tract infection and 5 episodes of
febrile neutropenia. Other grade 3 toxicities were rash (n¼2),
hypertension (n¼1), hypophosphatemia (n¼1) and hypo-
calcemia (n¼1). Twelve subjects, from cohorts 0, 1, 2 and 3
have reached day +100 response assessment. Distribution of
subjects by category of response before and after AHSCT is
displayed in Figure 2.
Conclusion: Conditioning with carﬁlzomib and melphalan
prior to AHSCT is well tolerated in patients with relapsed
MM. Final results of this phase 1 study will be presented at
the meeting. TheMTD cohort (or cohort 4 if noMTD is found)
will be subsequently expanded to 28 subjects for better
determination of this regimen’s activity and toxicity.228
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AL amyloidosis is a plasma cell dyscrasia. It is a rare and fatal
progressive disease inwhich abnormal proteins misfold, form
ﬁbrils and deposit in one or more vital organs causing per-
manent tissue damage and failure. Timely diagnosis is are
crucial to improve the patient’s ability to tolerate more
aggressive and effective therapies, thus increasing their
chance of disease control and improved survival. New drugs
and treatment regimens are now available in addition to high
dose melphalan and stem cell transplantation (HDM/SCT).
However, disease complexity and factors involved in deter-
mining a patient’s best treatment options remain a challenge.
Utilizing a multidisciplinary team approach is critical in
enhancing communication between the referring physicians,
the clinical team members and the patient regarding the
extent of disease and the treatment plan. Clinical pathwaysand standard operating procedures are followed throughout
disease evaluation and treatment. Medical records and
pathology specimens are reviewed prior to the scheduled
appointments in the Multidisciplinary Amyloid Clinic to
establish the accurate pathologic subtyping of each amyloid
precursor protein and determine the evaluation plan. Each
new patient typically meets with an Amyloid Internist, He-
matologist, Cardiologist, Nephrologist and other specialists as
indicated based on the patient’s organ involvement and co-
morbidities. If a clinical trial or HDM/SCT is included among
the treatment options, a Research Nurse and/or Transplant
Nurse Practitioner meets with the patient and family to pro-
vide a program overview and protocol speciﬁcs. Weekly
meetings involving different professionals specialized in the
amyloid diseases, including Hematologists, Internists, Pa-
thologists, Cardiologists, Nephrologists, Pulmonologists, Psy-
chiatrists, Nutritionists, Clinical Research Staff, Insurance
Coordinators and Nurse Practitioners are essential to indi-
vidualized patient care. During weekly patient conferences,
team members provide input regarding clinical assessments
and test results obtained during the two-day comprehensive
disease evaluation. At thesemeetings, individual patient cases
are discussed in detail, treatment options reviewed and clin-
ical trial eligibility determined. Following the multidisci-
plinary review, the Amyloid Team discusses with each patient
the recommendations, the involved risks and beneﬁts of the
different treatment options and the next steps to be taken. In
addition, all results and recommendations are discussed with
the referring physician. A multidisciplinary team approach
allows for a timely, efﬁcient and effective method to deter-
mine and administer safe care to patients, especially in a rare
and complex multi-system disease such as AL amyloidosis.229
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In AML patients despite intensive chemotherapy and addi-
tional stem cell transplantation, residual leukemic stem cells
(LSC) may lead to relapse. Therefore, elimination of LSC by
targeted therapy may represent a promising therapeutic
approach. Recently CD96was identiﬁed asmarker antigen on
AML LSC (Hosen et al., PNAS 104: 11008, 2007). Here, stra-
tegies for engineering autologous stem cell grafts as well as
for in vivo targeting of residual AML stem cells by addressing
CD96 for magnetic cell sorting (MACS) or antibody depen-
dent cellular cytotoxicity (ADCC) are described. To evaluate
the efﬁcacy of purging LSC by MACS technology, stem cell
containing grafts were spiked with CD96 positive AML cells.
Using biotinylated CD96 antibody TH111 raised in our labo-
ratory in combination with anti-Biotin-microbeads (Milte-
nyi) up to a 1000-fold depletion of targeted cells was
achieved. Viability, cell count and the potential of HPC to
proliferate and differentiate were not affected by this pro-
cedure as shown by ﬂow cytometry and colony forming as-
says. Eradication of AML stems cells is also an issue after
allogeneic stem cell transplantation. To target CD96+ AML-
LSC by ADCC, chimeric antibodies containing wild type or
afﬁnity maturated variable regions in combination with an
optimized human IgG1 Fc were generated. As shown by ﬂow
cytometry, the antigen binding afﬁnity of the maturated
antibody was enhanced (EC50 0.6 mg/ml vs. 2 mg/ml).
Moreover, also NK cell mediated lytic properties against
CD96-positive target cells were elevated (EC50: 0.02 mg/ml
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the purging strategy may be beneﬁcial for the development
of graft-engineering strategies to avoid transplantation of
AML-LSC and revitalize autologous stem cell transplantation
in this indication. The in vivo application may possibly open
additional therapeutic avenues in eliminating residual dis-
ease in autologous as well as allogeneic situations.
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Interim Results
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Background: The standard of care for patients (pts) with
Hodgkin lymphoma (HL) who are relapsed/refractory (R/R)
to frontline therapy is salvage chemotherapy followed by
autologous stem cell transplant (auto-SCT), with improved
outcomes reported for pts who achieve complete remission
(CR) prior to auto-SCT. Because standard therapies in the ﬁrst
relapse setting produce variable responses (19e60% CR rates)
and are associatedwith signiﬁcant toxicities, new treatments
are needed. Two highly active therapies in the second salvage
setting are the antibody-drug conjugate, brentuximab
vedotin (ADCETRIS) (34% CR; Younes, 2012), and the
bifunctional alkylating agent, bendamustine (33% CR; Mos-
kowitz, 2013). A phase 1/2, single-arm, 2-stage, open-label
study was designed to evaluate the safety and efﬁcacy of
brentuximab vedotin in combination with bendamustine for
treatment of HL in ﬁrst relapse. Interim results from the
phase 1 (safety) cohort are presented.
Methods: Pts receive brentuximab vedotin (1.8 mg/kg, up to
16 cycles), in combinationwith bendamustine (90mg/m2, up
to the ﬁrst 6 cycles). After Cycle 2, hematopoietic stem cells
are mobilized and collected for patients eligible for auto-SCT.
Response is assessed by the investigator per Cheson 2007.
Results: Six HL pts (5 females, 1 male) with a median age of
45 yrs (range, 20 to 61 yrs) have received at least 1 cycle of
brentuximab vedotin in combination with bendamustine.
Five pts are relapsed and 1 pt is primary refractory to front-
line chemotherapy. A median of approximately 16 mos
(range, 8 to 40 mos) have elapsed since the pts’ initial
diagnosis. To date, a maximum of 4 cycles of the combi-
nation regimen have been received and all patients remain
on treatment. Adverse events (AEs) reported for >1 pt are
nausea (4 pts); chills, ﬂushing, lymphopenia, and pyrexia (3
pts each); and constipation, dyspnea and throat tightness
(2 pts each). Three pts have had serious AEs: Gr 1 chills and
pyrexia in 1 pt, infusion-related reactions in 1 pt (Gr 1/2
throat tightness, urticaria, pyrexia, papular rash), and Gr 3
diarrhea (unrelated per the investigator) in 1 pt. Additional
Grade 3 AEs are lymphopenia (3 pts) and generalized rash
and dyspnea (1 pt each). No dose-limiting toxicities have
yet been reported. CR has been achieved in all 5 patients
who have been assessed for response (4 at Cycle 2 and 1 at
Cycle 4).
Conclusions: To date, brentuximab vedotin 1.8 mg/kg
administeredwith bendamustine 90mg/m2 has not exceededthe maximum tolerated dose and enrollment to this cohort is
ongoing. CR has been achieved in all patients who have been
assessed for response. Updated safety and response data, as
well as feasibility of stem cell mobilization and collection, will
be presented at the meeting.231
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Background: The role of allogeneic hematopoietic cell
transplantation (HCT) in multiple myeloma for consolidation
of initial response in the era of novel agents has not been
deﬁned. Therefore, we conducted a phase 2 study of alloge-
neic HCT in MM patients achieving at least very good partial
response (VGPR) after initial therapy.
Methods: Seventeen MM patients with ﬁrst VGPR or com-
plete remission (CR) received allogeneic HCT between 01/
2010 and 04/2013 at Mofﬁtt Cancer Center (NCT 00948922).
Eligible patients were age  60and have suitable HLA-
matched donors. All patients received either bortezomib or
lenalidomide (or both) based induction. Three patients (18%)
underwent autologous HCT with melphalan plus bortezomib
conditioning (MEL 200 plus bortezomib 1.3 mg/m2) after
induction for cytoreduction. Conditioning regimen before
allogeneic HCT consisted of ﬂudarabine 30 mg/m2 x 4 days
and melphalan 70 mg/m2 x 2 days followed by bortezomib
1.3 mg/m2 (Flu/Mel/Vel). GVHD prophylaxis was tacrolimus
plus either methotrexate (n¼9), or mycophenolate mofetil
(n¼4), or sirolimus (n¼4). No maintenance therapy was
prescribed.
Results: The median age at transplant was 51 (25 e 57)
years. Seven patients (41%) have high-risk cytogenetics/
FISH. Disease status at the time of allogeneic HCT was VGPR
(n¼8), CR (n¼3), or stringent CR (n¼6). All patients received
unmanipulated peripheral blood stem cell grafts from HLA-
matched sibling donors (n¼7) or 8/8 HLA-matched unre-
lated donors (n¼10). Neutrophil engraftment was achieved
at a median of 14 (11 - 18) days and platelet engraftment
with a median of 17 (13 - 21) days. Best responses after
allogeneic HCT were CR (n¼2), sCR (n¼13), and disease
progression (n¼2). The 2-year progression-free survival es-
timate is 80% (95%CI: 51 e 98) for standard-risk and 51%
(95%CI: 15 e 87) for high-risk, respectively. With a median
follow up of 18 (3 - 43) months, the 2-year overall survival
estimate is 88% (95%CI: 68 e 99). The cumulative incidence
of non-relapse mortality was 6% (95%CI: 0.0 e 22) at 100
days and 13% (95%CI: 1 e 34) at 1 year, respectively. The
cumulative incidence of grades 2-4 acute GVHD at day 100
was 41% (95% CI: 20 e 65) and the cumulative incidence of
moderate to severe chronic GVHD at 1 year was 8.0% (95%
CI: 0.0 e 29).
Conclusions: These results indicate that allogeneic HCT for
MM in VGPR or CR as consolidation achieves favorable dis-
ease control. The study is ongoing to assess long-term safety
of this modality. Amulticenter trial is planned to evaluate the
utility of allogeneic HCT in high-risk MM.
